Trials / Completed
CompletedNCT02639182
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGS-16C3F | Intravenous (IV) infusion |
| DRUG | Axitinib | Oral |
Timeline
- Start date
- 2016-05-03
- Primary completion
- 2020-10-02
- Completion
- 2020-10-02
- First posted
- 2015-12-24
- Last updated
- 2024-11-18
- Results posted
- 2020-09-23
Locations
26 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02639182. Inclusion in this directory is not an endorsement.